COMPLETED

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Talk to us

Conditions

Central Nervous System LymphomaDiffuse Large B-Cell Lymphoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Official Title

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Quick Facts

Study Start:2023-05-10
Study Completion:2025-12-23
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06031194

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * \* Adult (age ≥ 18 years at diagnosis)
  2. * Diagnosis of DLBCL or PCNSL
  3. * Planned to undergo treatment with HDMTX (≥ 3 g/m\^2) at the James Cancer Hospital.
  4. * Ability to provide informed consent.
  1. * \* Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation
  2. * Pregnancy (positive serum or urine pregnancy test), lactating or breast feeding
  3. * Prisoners or incarcerated patients
  4. * Total bilirubin \> 5 mg/dL

Contacts and Locations

Principal Investigator

Timothy Voorhees, MD
PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center

Study Locations (Sites)

Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
United States

Collaborators and Investigators

Sponsor: Ohio State University Comprehensive Cancer Center

  • Timothy Voorhees, MD, PRINCIPAL_INVESTIGATOR, Ohio State University Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-10
Study Completion Date2025-12-23

Study Record Updates

Study Start Date2023-05-10
Study Completion Date2025-12-23

Terms related to this study

Additional Relevant MeSH Terms

  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma